Blood clot drug trial for rare autoimmune disease pulled before start
NCT ID NCT07172022
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood platelet trends may reveal hidden risk in autoimmune disease
- Immune clues in the blood may foretell heart trouble
- Can a simple blood test tell two forms of a clotting disorder apart?
- New fingerstick test for blood thinner monitoring put to the test
- New MRI study seeks hidden stroke causes in rare blood disorder
- New hope for stroke survivors with rare clotting disorder: rivaroxaban vs warfarin